Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.85 - $3.2 $291,190 - $503,680
-157,400 Reduced 77.73%
45,100 $98,000
Q2 2024

Aug 15, 2024

BUY
$2.31 - $5.59 $161,469 - $390,741
69,900 Added 52.71%
202,500 $467,000
Q1 2024

May 07, 2024

BUY
$1.9 - $10.13 $191,900 - $1.02 Million
101,000 Added 319.62%
132,600 $729,000
Q4 2023

Feb 14, 2024

SELL
$2.08 - $31.18 $124,592 - $1.87 Million
-59,900 Reduced 65.46%
31,600 $78,000
Q3 2023

Nov 14, 2023

SELL
$29.8 - $40.3 $2.1 Million - $2.84 Million
-70,500 Reduced 43.52%
91,500 $3.18 Million
Q2 2023

Aug 11, 2023

BUY
$28.53 - $39.55 $3.62 Million - $5.02 Million
127,000 Added 362.86%
162,000 $5.31 Million
Q1 2023

May 16, 2023

BUY
$29.51 - $46.65 $1.03 Million - $1.63 Million
35,000 New
35,000 $1.17 Million
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $452,512 - $1.39 Million
35,800 New
35,800 $1.25 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $116M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.